article · Bioanalysis
BACKGROUND: Simultaneous therapeutic drug monitoring of metformin (MEF) and empagliflozin (EMP) in plasma requires sustainable, white analytical chemistry (WAC) methods. Existing techniques suffer from poor greenness, electrode modification complexity, and limited plasma applicability. RESEARCH DESIGN AND METHODS: = 9). RESULTS: = 5. Whiteness: 97/100 (RGB-12); greenness: 83/100 (MOGABI) - superior to reported methods. CONCLUSIONS: Validated DPV-GCE enables rapid, sustainable MEF/EMP quantification in plasma without modification/chromatography. Proof-of-concept for routine therapeutic monitoring; clinical translation limited by spiked (not patient) samples.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/17576180.2026.2630071
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
